Active, not recruitingNCT06002945
Exploring Outcomes and Characteristics of Myasthenia Gravis 2
Studying Adult-onset myasthenia gravis
Last synced from ClinicalTrials.gov
ℹ
Clinical trial records are synced from ClinicalTrials.gov through automated extraction.
Report missing dataKey facts
- Sponsor
- Yale University
- Principal Investigator
- Richard Nowak, MD, MDYale University
- Intervention
- Blood sample(other)
- Enrollment
- 400 enrolled
- Eligibility
- 18 years · All sexes
- Timeline
- 2021 – 2026
Study locations (10)
- University of California-Irvine, Irvine, California, United States
- Cedars Sinai Medical Center, Los Angeles, California, United States
- Yale University, New Haven, Connecticut, United States
- George Washington University, Washington D.C., District of Columbia, United States
- University of Chicago, Chicago, Illinois, United States
- Massachusetts General Hospital, Boston, Massachusetts, United States
- University of North Carolina, Chapel Hill, North Carolina, United States
- Duke University Medical Center, Durham, North Carolina, United States
- Wake Forest University, Winston-Salem, North Carolina, United States
- Medical University of South Carolina, Charleston, South Carolina, United States
Collaborators
National Center for Advancing Translational Sciences (NCATS) · National Institute of Neurological Disorders and Stroke (NINDS)
Primary source
Recruitment status, site addresses, contacts, and full eligibility criteria can change between syncs. Always verify with the trial team before planning travel or treatment.
Open NCT06002945 on ClinicalTrials.govOther trials for Adult-onset myasthenia gravis
Additional recruiting or active studies for the same condition.
- RECRUITINGPHASE2NCT06987539A Study to Evaluate the Pharmacokinetics, Pharmacodynamics, Safety and Tolerability of Inebilizumab in Children With Generalized Myasthenia Gravis (gMG)Amgen
- RECRUITINGPHASE2NCT07501702A Phase 2 Study to Evaluate Povetacicept in Adults With Generalized Myasthenia GravisVertex Pharmaceuticals Incorporated
- RECRUITINGPHASE1NCT07526493Safety and Pharmacodynamics of QH103 Cell Injection in the Treatment of Patients With Relapsed/Refractory Antibody-Mediated Neurological Autoimmune Diseases.Tongji Hospital
- RECRUITINGNANCT07413835Efficacy and Safety of HN2302 in Refractory Myasthenia Gravis(MG)The Affiliated Hospital of Xuzhou Medical University
- RECRUITINGPHASE1, PHASE2NCT07089121Descartes-08 for Children, Adolescents, and Young Adults With Autoimmune DisordersCartesian Therapeutics
- RECRUITINGPHASE1NCT07304154A Study Evaluating the Safety and Efficacy of KITE-363 in Relapsed/Refractory Autoimmune Neurologic DiseasesKite, A Gilead Company
- RECRUITINGPHASE4NCT07221838A Study to Investigate OCS Tapering in Adult Participants With Generalized Myasthenia Gravis Treated With RavulizumabAlexion Pharmaceuticals, Inc.
- RECRUITINGPHASE1, PHASE2NCT07250750A Phase 1b/2 Study of IM-101 in Adult Participants With Generalized Myasthenia Gravis and Ocular Myasthenia GravisImmunAbs Inc.